![Transient Elastography Research Hotspots and Frontiers in Nonalcoholic Fatty Liver Disease: A Bibliometric Study Using CiteSpace Transient Elastography Research Hotspots and Frontiers in Nonalcoholic Fatty Liver Disease: A Bibliometric Study Using CiteSpace](https://publinestorage.blob.core.windows.net/c4f3f31c-843a-4092-85b0-1625bbbfe341/erhm-21-64-g010.jpg)
Transient Elastography Research Hotspots and Frontiers in Nonalcoholic Fatty Liver Disease: A Bibliometric Study Using CiteSpace
![Frontiers | Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter Frontiers | Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter](https://www.frontiersin.org/files/Articles/788881/fmed-08-788881-HTML-r1/image_m/fmed-08-788881-g001.jpg)
Frontiers | Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
![Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine](https://www.thelancet.com/cms/asset/237b6cc2-db03-407a-a4f3-d3e37f33891b/gr2.jpg)
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine
Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study | PLOS ONE
![Diagnostics | Free Full-Text | Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan Diagnostics | Free Full-Text | Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan](https://www.mdpi.com/diagnostics/diagnostics-10-00159/article_deploy/html/images/diagnostics-10-00159-g001.png)
Diagnostics | Free Full-Text | Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
![Diagnostics | Free Full-Text | Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches Diagnostics | Free Full-Text | Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches](https://pub.mdpi-res.com/diagnostics/diagnostics-12-00407/article_deploy/html/images/diagnostics-12-00407-g001.png?1644571167)
Diagnostics | Free Full-Text | Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches
![Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-93294-6/MediaObjects/41598_2021_93294_Fig1_HTML.png)
Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports
![Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination | Scientific Reports Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-75227-x/MediaObjects/41598_2020_75227_Fig1_HTML.png)
Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination | Scientific Reports
![Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-021-01388-2/MediaObjects/12933_2021_1388_Fig1_HTML.png)
Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study
![PDF) Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan PDF) Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan](https://i1.rgstatic.net/publication/339994413_Non-Alcoholic_Fatty_Liver_Disease_in_Patients_with_Type_2_Diabetes_Evaluation_of_Hepatic_Fibrosis_and_Steatosis_Using_Fibroscan/links/5e71774d299bf15718459fa9/largepreview.png)
PDF) Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
![Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-93294-6/MediaObjects/41598_2021_93294_Fig2_HTML.png)
Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports
![Diagnostics | Free Full-Text | Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan Diagnostics | Free Full-Text | Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan](https://www.mdpi.com/diagnostics/diagnostics-10-00159/article_deploy/html/images/diagnostics-10-00159-g002.png)